NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its second quarter net loss swelled year over year as it continues to advance its flagship liquid biopsy test toward commercialization.

For the three months ended June 30, the Alameda, California-based diagnostic developer incurred a net loss of $4.5 million, or $.12 per share, compared to a loss of $3.8 million, or $.13 per share, in the year-ago period. Analysts on average had expected a loss per share of $.09.

OncoCyte did not report any Q2 revenues, the same as in the year-ago quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.